



Cadence Pharmaceuticals' CEO Ted Schroeder to Present at the JMP Securities Healthcare Focus Conference in New York on October 6, 2009

SAN DIEGO, Sept 29, 2009 /PRNewswire-FirstCall via COMTEX News Network/ -- Cadence Pharmaceuticals, Inc. (Nasdaq: CADX), a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting, announced today that the company's President and CEO Ted Schroeder will present the company's corporate overview on Tuesday, October 6, 2009 at 2:00pm Eastern Time (11:00am Pacific Time) during the JMP Securities Healthcare Focus Conference at the Palace Hotel in New York City.

The presentation will be simultaneously webcast and can be accessed on Cadence Pharmaceuticals' website at www.cadencepharm.com in the Investor Relations section. A replay of the webcast will be available approximately three hours following the live webcast and will be archived for 90 days.

About Cadence Pharmaceuticals, Inc.

Cadence Pharmaceuticals is a biopharmaceutical company focused on in-licensing, developing and commercializing proprietary product candidates principally for use in the hospital setting. The company is currently developing Acetavance(TM) (intravenous acetaminophen), its investigational product candidate for the treatment of acute pain and fever. For more information about Cadence's pipeline, visit www.cadencepharm.com.

Cadence(TM) and Acetavance(TM) are trademarks of Cadence Pharmaceuticals, Inc.

Contacts: William R. LaRue
SVP, CFO
Cadence Pharmaceuticals, Inc.
858-436-1400

SOURCE Cadence Pharmaceuticals, Inc.

<http://www.cadencepharm.com>

Copyright (C) 2009 PR Newswire. All rights reserved